Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05428592
Other study ID # LVRNA009-?-02
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date April 2023
Est. completion date October 2024

Study information

Verified date June 2022
Source AIM Vaccine Co., Ltd.
Contact Fan Zhang
Phone 021-33360772
Email fan.zhang@aimbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a randomized, blinded, parallel-controlled phase 3 clinical trial. The study intent to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as heterologous booster in participants aged 18 years and older vaccinated 2 doses Inactivated SARS-CoV-2 Vaccine.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1100
Est. completion date October 2024
Est. primary completion date October 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults aged 18 years and older. 2. Understand the contents of the ICF and voluntarily sign it (If the participant is unable to sign the ICF on his/her own due to illiteracy, an impartial witness is needed). 3. Participants who are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, and other study procedures. 4. Female participants of childbearing potential or partners of male participants: voluntarily agree to use effective contraception with their partners 14 days prior to the vaccination and must agree to continue such precautions during the study until 3 months after vaccination. [Effective contraception includes oral contraceptives, injectable or implantable contraception, extended-release topical contraceptives, hormonal patches, intrauterine devices (IUDs), sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.]. 5. For female participants: without childbearing potential (amenorrhea for at least 1 year or documented surgical sterilization) or have used effective contraception with a negative pregnancy test before vaccination in this study. 6. Axillary temperature <37.3°C/99.1°F at screening visit and 72 hours prior to vaccination. 7. Healthy participants or participants with mild underlying disease [in a stable state without exacerbation (no admission to hospital or no major adjustment to treatment regimen, etc.) for at least 3 months prior to enrollment in this study]. 8. Participants who have vaccinated 2 doses of CoronaVac® (with an interval of 3-8 weeks between 2 doses), for 6-12 months prior to enrollment. Exclusion Criteria: 1. Previous medications intervention for the prophylaxis or prevention of COVID-19 (Including vaccination with any licensed SARS-CoV-2 vaccines other than 2 doses of CoronaVac® ). 2. History of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) or other coronavirus infections. 3. History of a previous laboratory-confirmed diagnosis of SARS-CoV-2 infection or COVID-19. 4. History of allergy to any component of the study vaccine or history of severe allergic reaction to the vaccine or drug (including but not limited to anaphylaxis, allergic laryngeal oedema, anaphylactic purpura, thrombocytopenic purpura, or localized allergic necrosis (Arthus reaction)). 5. Positive nucleic acid for SARS-CoV-2 in nasopharyngeal/oropharyngeal swab specimens. 6. Positive HIV test result. 7. A history or family history of convulsions, epilepsy, encephalopathy and psychosis. 8. Malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period. 9. Congenital or functional splenic deficiency, complete or partial splenectomy for any reason. 10. Prolonged (defined as more than 14 days) use of immunosuppressive or other immunomodulatory drugs (e.g., corticosteroids, =20 mg/d prednisone or equivalent; however, inhaled and topical steroids are permitted) within 6 months prior to the vaccine. 11. Any other licensed vaccines given within 28 days prior to the study vaccination, or planned administration of vaccine(s) within 28 days after vaccination. 12. Have received immunoglobulin or other blood products within 3 months prior to enrollment or plan to receive them during the study period. 13. Blood donation or blood loss = 450 mL within 1 month prior to enrolment, or planned donation during the study period. 14. Participants who have received any other investigational product within 1 month prior to enrollment or intent to participate in another clinical study at any time during the conduct of this study. 15. Female participants who are pregnant or breastfeeding. 16. Participants deemed unsuitable for participation in this study based on the investigator's assessment.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
LVRNA009
50µg /0.5 mL/Vial/person
CoronaVac®
0.5 mL/Vial, 0.5mL per human dose containing 600SU of inactivated SARS-CoV-2 antigen

Locations

Country Name City State
Pakistan Clinical Trial Unit, National Institute of Health Islamabad

Sponsors (1)

Lead Sponsor Collaborator
AIM Vaccine Co., Ltd.

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Other Cellular immune subgroup: virus antigen-specific IL-2, IL-4, IL-13, IFN-? cytokine titers (ELISpot) 7 days, 14 days, and 28 days after vaccination
Other Cross-neutralization subgroup: cross-neutralizing ability of VNA (live virus neutralizing assay) against other VOCs of SARS-CoV-2 14 and 28 days after vaccination
Primary Geometric mean titer (GMT) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay) 14 days after vaccination for all participants
Primary Seroconversion Rate (SCR) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay) Seroconversion is defined as: GMT post vaccination= 4-fold rise from baseline GMT value 14 days after vaccination for all participants
Primary Incidence of each solicited (local and systemic) AE and each unsolicited AE AE within 14 days, unsolicited AE within 28 days after vaccination for all participants
Primary Intensity of each solicited (local and systemic) AE and each unsolicited AE AE within 14 days, unsolicited AE within 28 days after vaccination for all participants
Primary Duration of each solicited (local and systemic) AE and each unsolicited AE AE within 14 days, unsolicited AE within 28 days after vaccination for all participants
Secondary Geometric mean increase (GMI) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay) 14 days after vaccination for all participants
Secondary GMT of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay) 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Secondary SCR of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay) 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Secondary GMI of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay) 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Secondary GMT of SARS-CoV-2 (Wild-type strain) VNA (pseudo-virus neutralizing assay) 14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Secondary SCR of SARS-CoV-2 (Wild-type strain) VNA (pseudo-virus neutralizing assay) 14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Secondary GMI of SARS-CoV-2 (Wild-type strain) VNA (pseudo-virus neutralizing assay) 14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Secondary GMT of S-protein specific IgG antibodies (ELISA) 14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Secondary SCR of S-protein specific IgG antibodies (ELISA) 14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Secondary GMI of S-protein specific IgG antibodies (ELISA) 14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Secondary Incidence of serious adverse events (SAEs), adverse events of special interest (AESI), and the occurrence of pregnancy events within 12 months after vaccination for all participants
Secondary Intensity of serious adverse events (SAEs), adverse events of special interest (AESI), and the occurrence of pregnancy events within 12 months after vaccination for all participants
Secondary Causality of serious adverse events (SAEs), adverse events of special interest (AESI), and the occurrence of pregnancy events within 12 months after vaccination for all participants
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Active, not recruiting NCT05550142 - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China N/A
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A